Product Description
"
Cobimetinib (GDC-0973, XL-518, Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It was studied in combination with vemurafenib, a BRAF inhibitor, to treat several cancers.
In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib
"
![2758367-55-2,Thiophenium, 1-[4-(1,1-dimethylethyl)phenyl]tetrahydro-, bromide (1:1)](https://www.pudeepharm.com/wp-content/uploads/2026/05/20260525040002947046.webp)
